Observations placeholder
Phentermine
Identifier
005759
Type of Spiritual Experience
Background
A description of the experience
Phentermine - Is a contraction of "phenyl-tertiary-butylamine", is an appetite suppressant. It is an amphetamine like stimulant.
The marketing literature describes it thus "Phentermine stimulates the adrenal glands to release norepinephrine, a neurotransmitter or chemical messenger that signals a fight-or-flight response, reducing hunger. Phentermine works outside the brain as well to release epinephrine or adrenaline causing fat cells to break down stored fat, but the principal basis of efficacy is hunger-reduction. At clinically relevant doses, phentermine also releases serotonin and dopamine, but to a much lesser extent than that of norepinephrine".
Phentermine is a stimulant and as such produces tachycardia (increased heart rate), elevated blood pressure, palpitations, restlessness, and insomnia. Additionally, phentermine has the potential to cause psychological dependence. After short term use, tolerance begins and can be followed by rebound weight gain. Side effects include
-
Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache.
-
Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.
-
Urticaria, endocrine Impotence, changes in libido.
-
Convulsions, seizures, hallucinations, aggression, light headedness, mania and depression, tremors
Because it is similar to amphetamines, it is classified as a controlled substance in many countries. Internationally, phentermine is a schedule IV drug under the Convention on Psychotropic Substances. Trade names include………..
-
Adipex & Adipex-p
Adiphene (India)
Anoxine-
Ionamin
Duromine
Metermine
Mirapront
Obephen
Obermine
Obestin-30
Phentremine
Phentrol
Phenterex
Fastin
Phentromin
Pro-Fast SA
Qnexa (with Topiramate)
Redusa
Panbesy
Phentermine Trenker
Obenix
Oby-Trim
Teramine
Zantryl
Sinpet (MX)
Supremin (PH)
Umine (NZ) ,
Weltmine (KP)
Again more marketing information................
Indications |
Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m2, or ≥ 27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, hyperlipidemia). The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. |
Dosage |
Exogenous Obesity: Dosage should be individualized to obtain an adequate response with the lowest effective dose. The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1 to 2 hours after breakfast. The dosage may be adjusted to the patient's need. For some patients 1/2 tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give 1/2 tablet (18.75 mg) two times a day. Late evening medication should be avoided because of the possibility of resulting insomnia. Phentermine is not recommended for use in patients sixteen (16) years of age and under. |
Overdosage |
Manifestations of acute overdosage with phentermine include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma. Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine®, CIBA) has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage. |
On Feb, 27, 2015: 11,008 people reported to have side effects when taking Phentermine. Among them, 23 people (0.21%) have Hallucination.
On Jun, 20, 2015: 11,032 people reported to have side effects when taking Phentermine. Among them, 42 people (0.38%) have Death.
The source of the experience
eHealthmeConcepts, symbols and science items
Concepts
Symbols
Science Items
Activities and commonsteps
Activities
Overloads
Amphetamines and stimulantsNarcolepsy treatments
Obesity treatments
Releasing agents